MedTrace Logo

Trazodone for SSRI-sexual Dsyfunction

NCT01097980 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2012-04-24

No results posted yet for this study

Summary

The aim of this study is to investigate the efficacy of trazodone in the treatment of selective serotonin reuptake inhibitor(s) associated sexual dysfunction. The secondary domains assessed were the relationship between 5-HT2A polymorphism and treatment efficacy.

Conditions

  • Sexual Dysfunction

Interventions

DRUG

Trazodone

50 mg/d trazodone was upwardly titrated to 100 mg/d over one week and then maintained

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Beitou Armed Forces Hospital, Taipei, Taiwan

    lead OTHER_GOV

Principal Investigators

  • Kuo-Tung Chiang, M.D. · Department of Psychiatry, Beitou Armed Forces Hospital, Taipei, Taiwan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2012-01-31
Completion
2012-01-31

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01097980 on ClinicalTrials.gov